Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2018

  1. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

    Breast Cancer Research and Treatment, Vol. 169, Núm. 3, pp. 469-479

  2. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133

2016

  1. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

    Oncotarget, Vol. 7, Núm. 25, pp. 37680-37692